Axsome Therapeutics, Inc.
AXSM
$118.51
$1.371.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 495.03M | 432.16M | 385.69M | 338.46M | 291.49M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 495.03M | 432.16M | 385.69M | 338.46M | 291.49M |
| Cost of Revenue | 42.19M | 36.80M | 33.30M | 30.17M | 28.26M |
| Gross Profit | 452.85M | 395.36M | 352.39M | 308.29M | 263.23M |
| SG&A Expenses | 459.90M | 433.18M | 411.36M | 384.90M | 372.52M |
| Depreciation & Amortization | 6.37M | 6.38M | 6.39M | 6.39M | 6.39M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 703.18M | 671.38M | 638.13M | 584.33M | 553.43M |
| Operating Income | -208.15M | -239.22M | -252.44M | -245.87M | -261.94M |
| Income Before Tax | -247.78M | -278.19M | -287.13M | -311.28M | -309.56M |
| Income Tax Expenses | -875.00K | 85.00K | 85.00K | -325.00K | -1.00M |
| Earnings from Continuing Operations | -246.90 | -278.27 | -287.22 | -310.96 | -308.55 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -246.90M | -278.27M | -287.22M | -310.96M | -308.55M |
| EBIT | -208.15M | -239.22M | -252.44M | -245.87M | -261.94M |
| EBITDA | -199.64M | -230.96M | -244.48M | -238.25M | -254.63M |
| EPS Basic | -5.07 | -5.77 | -6.00 | -6.54 | -6.51 |
| Normalized Basic EPS | -2.78 | -3.20 | -3.38 | -3.30 | -3.51 |
| EPS Diluted | -5.08 | -5.77 | -6.00 | -6.54 | -6.51 |
| Normalized Diluted EPS | -2.78 | -3.20 | -3.38 | -3.30 | -3.51 |
| Average Basic Shares Outstanding | 195.00M | 193.13M | 191.65M | 190.44M | 189.41M |
| Average Diluted Shares Outstanding | 195.00M | 193.13M | 191.65M | 190.44M | 189.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |